Tyrosine kinase inhibitorFDA-approvedSecond-line
Mektovi
Generic name: binimetinib
How it works
Binimetinib blocks the MEK1 and MEK2 enzymes, which are involved in the MAPK signaling pathway.
Cancer types
Colorectal Cancer— BRAF V600E-mutated
Efficacy
In clinical trials, binimetinib improved response rates and overall survival in patients with metastatic colorectal cancer harboring the BRAF V600E mutation.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Cancer Treatment Combination in Advanced Tumors | Breast Cancer | phase-1 | — | Source → |
| Testing Binimetinib for Relapsed/Refractory Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Encorafenib Plus Binimetinib for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Binimetinib and Imatinib for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Combining Futibatinib and Binimetinib in Advanced Cancer Treatment | Lung Cancer | phase-1 | — | Source → |
| Researchers Identify Potential Biomarkers for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | In patients treated with binimetinib, the response rate was 41% in those with MAPK pathway alterations, and 13% in those without. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.